EUVIMEDEUVIMED entdecken
Crossref

Anti‐Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross‐Sectional Study

Samuel Truniger iD, David Waber, Joel Dütschler, Marius König, Jakob Heimer, Peter Schönenberger, Seraina Koller, Isabelle Kamm, Regine Garcia Boy, Christina Lins, Claudia Krieger iD, Nicola Fabian Frei iD und 4 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Samuel Truniger und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, HOCH Health Ostschweiz, St. Gallen, Switzerland. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Antibodies, Antineutrophil Cytoplasmic, Autoantibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Crohn's and Colitis UK, Lee Placito Medical Fund, Oxford Colon Cancer Trust (Occtopus).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reliable biomarkers to distinguish ulcerative colitis (UC) from Crohn's disease (CD) remain limited.

Aims

To assess the diagnostic accuracy of anti‐integrin αvβ6 autoantibodies for differentiating UC from CD and to compare their performance with anti‐neutrophil cytoplasmic antibodies (ANCA) and anti‐ Saccharomyces cerevisiae antibodies (ASCA).

Methods

In this prospective cross‐sectional study in patients with UC and CD, serum anti‐integrin αvβ6 autoantibodies, ASCA, and ANCA were measured and clinical data were collected. The primary outcome was the accuracy of anti‐integrin αvβ6 antibodies in distinguishing UC from CD. Secondary analyses compared their performance with ASCA and ANCA status and across IBD subgroups.

Results

A total of 224 patients were included (UC: n = 106, CD: n = 118, male: 63.8%, median age: 43.5 years). Patients with indeterminate colitis were excluded. At a cut‐off of 2.44 U/mL, anti‐integrin αvβ6 autoantibodies demonstrated a diagnostic accuracy of 86.5%, with a sensitivity of 85.8% and specificity of 87.1%. In a multivariate logistic regression analysis, these autoantibodies were independently associated with UC (OR 36.18, 95% CI 17.0–83.0, p = 4.86 × 10 −19 ) and demonstrated superior diagnostic performance compared to ANCA and ASCA status (Akaike information criterion 184.8 vs. 252.4). Positivity rates followed a gradient across the Montreal classification, increasing from ileal (L1: 7.9%) and ileocolonic (L3: 8.1%) CD towards colonic CD (L2: 43.8%) and UC: 85.8% ( p = 2.04 × 10 −31 ).

Conclusions

Anti‐integrin αvβ6 autoantibodies demonstrate high diagnostic accuracy and outperform conventional serological markers in distinguishing UC from CD. Importantly, this study provides the first direct comparison with ANCA and ASCA status within the same patient cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseAntibodies, Antineutrophil CytoplasmicAutoantibodiesSaccharomyces cerevisiaeIntegrinsAntigens, NeoplasmAntibodies, FungalHumansProspective StudiesCross-Sectional StudiesAdultMaleBiomarkersFemaleMiddle AgedDiagnosis, DifferentialSensitivity and Specificity

Stichwörter der Autor:innen

Crohn's diseaseanti‐Saccharomyces cerevisiae antibodies (ASCA)anti‐integrin αvβ6 antibodiesanti‐neutrophil cytoplasmic antibodies (ANCA)autoantibodiesinflammatory bowel diseaseulcerative colitis

Substanzen

Antibodies, Antineutrophil CytoplasmicAutoantibodiesBiomarkersIntegrinsintegrin alphavbeta6Antigens, NeoplasmAntibodies, Fungal

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, HOCH Health Ostschweiz, St. Gallen, Switzerland.
  • Department of General Internal Medicine, HOCH Health Ostschweiz, St. Gallen, Switzerland.
  • Clinical Trial Unit, HOCH Health Ostschweiz, St. Gallen, Switzerland.
  • Centre for Laboratory Medicine, St. Gallen, Switzerland.
  • Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Ludwig Maximilian University (LMU), Munich, Germany.
  • Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

ORCID-Profile: Samuel Truniger, Claudia Krieger, Nicola Fabian Frei, Simon Woelfel, Stephan Brand

Förderung

  • Crohn's and Colitis UK
  • Lee Placito Medical Fund
  • Oxford Colon Cancer Trust (Occtopus)
  • HOCH Health Ostschweiz, Cantonal Hospital St. Gallen
  • Wellcome Trust
  • Medical Research Council

Zitieren

APA

Truniger, S., Waber, D., Dütschler, J., König, M., Heimer, J., Schönenberger, P., Koller, S., Kamm, I., Boy, R. G., Lins, C., Krieger, C., Frei, N. F., Woelfel, S., Friedrich, M., Mahr, A., & Brand, S. (2026). Anti‐Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross‐Sectional Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70926

Vancouver

Truniger S, Waber D, Dütschler J, König M, Heimer J, Schönenberger P, et al. Anti‐Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross‐Sectional Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70926

BibTeX
@article{Truniger2026,
  author = {Truniger, Samuel and Waber, David and Dütschler, Joel and König, Marius and Heimer, Jakob and Schönenberger, Peter and Koller, Seraina and Kamm, Isabelle and Boy, Regine Garcia and Lins, Christina and Krieger, Claudia and Frei, Nicola Fabian and Woelfel, Simon and Friedrich, Matthias and Mahr, Alfred and Brand, Stephan},
  title = {Anti‐Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross‐Sectional Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70926}
}
Kostenlos starten →